trending Market Intelligence /marketintelligence/en/news-insights/trending/hgdkszr1zzsnlxiasnayfw2 content esgSubNav
In This List

Bovie Medical to change name to Apyx Medical, focus on cosmetic surgery market

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Bovie Medical to change name to Apyx Medical, focus on cosmetic surgery market

Bovie Medical Corp. will change its name to Apyx Medical Corp., effective Jan. 1, 2019, as it plans to focus on the cosmetic surgery market following the sale of its core business to Symmetry Surgical Inc. in August.

The Clearwater, Fla.-based medical device maker also plans to move its listing to the Nasdaq Global Select Market from the New York Stock Exchange and expects its common stock to start trading Jan. 2, 2019, under a new ticker, APYX.

Bovie President and CEO Charlie Goodwin said the name change emphasizes the company's focus on the cosmetic surgery market and the broader medical technology sector following a restructuring of its business.

The company sold its core electrosurgical and cauteries business while retaining its advanced energy and original equipment manufacturer, or OEM, businesses. The company said it plans to focus on the commercialization of its J-plasma technology —advanced energy device used for controlled cutting, coagulation and ablation in plastic and gynecological surgery procedures — under the Renuvion brand.